Search All UT System Experts

ENGINE: A Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1

Grzegorz S. Nowakowski, Jun Zhu, Qingyuan Zhang, Joshua Brody, Xiuhua Sun, Joseph Maly, Yuqin Song, Syed Rizvi, Yongping Song, Frederick Lansigan, Hongmei Jing, Junning Cao, Jennifer K. Lue, Wen Luo, Lei Zhang, Ling Li, Isabel Han, Joan Sun, Manoj Jivani, Young LiuThomas Heineman, Stephen D. Smith

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'ENGINE: A Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1'. Together they form a unique fingerprint.

Medicine & Life Sciences